Results 51 to 60 of about 12,794 (204)
Clinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 608-617, March 2026.This manuscript describes the scope of implementation and impact of a regulatory agency‐qualified panel of six urine biomarkers on drug development, the process for which was conducted and funded by the Critical Path Institute, the Foundation for the National Institutes of Health, and the United States Food and Drug Administration.
Tanja S. Zabka +7 more
wiley +1 more source
Results of A Local Combination Therapy Antibiogram For \u3cem\u3ePseudomonas Aeruginosa\u3c/em\u3e Isolates: Is Double Worth The Trouble? [PDF]
, 2017 Purpose: To determine the frequency at which fluoroquinolones and aminoglycosides demonstrate in vitro activity against non-urinary, non-skin/skin structure Pseudomonas aeruginosa isolates exhibiting decreased susceptibilities to one or more β-lactam ...
Davis, Jim +4 more
core +1 more source
A cost analysis of a broad-spectrum antibiotic therapy in the empirical treatment of health care-associated infections in cirrhotic patients [PDF]
, 2017 Background: Early diagnosis and appropriate treatment of infections in cirrhosis are crucial. As new guidelines in this context, particularly for health care-associated (HCA) infections, would be needed, we performed a trial documenting whether an ...
Ceccarelli, Giancarlo +5 more
core +2 more sources
Journal of Materials Science: Materials in Medicine, 2023 Numerous infections are linked to Pseudomonas aeruginosa. It is one of the major medical concerns because of virulence and antibiotic resistance.
Faezeh Milani +5 more
doaj +1 more source
Small Science, Volume 6, Issue 3, March 2026.Current treatments for severe lupus nephritis are limited by side effects due to poor drug targeting. This review explores how smart nanomaterials—like liposomes and biomimetic carriers—can precisely deliver drugs to overactive immune cells and the kidneys. These nanotherapeutics enhance efficacy, reduce toxicity, and enable combination strategies. The
Cheng Zhou +6 more
wiley +1 more source
Monotherapy in serious hospital-acquired infections: a clinical trial of ceftazidime versus imipenem/cilastatin [PDF]
, 2017 The clinical and bacteriological efficacy and safety of the antibiotics ceftazidime or imipenem/cilastatin in seriously ill patients with nosocomial infections were compared in a prospective, open, evaluator-blind, multicentre comparative trial.
Finch, Roger G. +2 more
core
BMC Nephrology, 2019 Background Cilastatin (CL) is an inhibitor of dehydropeptidase-I, which is safely used in clinical practice to prevent nephrotoxicity of antibiotics.
Kang Luo +7 more
doaj +1 more source
Clinical Case Reports, Volume 14, Issue 2, February 2026.ABSTRACT In patients in peritoneal dialysis (PD) who develop exit site and/or catheter tunnel infections, expeditious identification of the causative organism and early implementation of treatment are important to ensure good outcomes. Among the many causative organisms, the diagnosis of Mycobacterium fortuitum is particularly challenging, with its ...
Rina Takahashi +4 more
wiley +1 more source
A systematic review of cost-effectiveness analyses of complex wound interventions reveals optimal treatments for specific wound types. [PDF]
, 2015 BackgroundComplex wounds present a substantial economic burden on healthcare systems, costing billions of dollars annually in North America alone.
Antony, Jesmin +7 more
core +3 more sources
SAPD PERİTONİTİNİN TEDAVİSİNDE IMIPENEM/CILASTATIN
Turkish Journal of Nephrology, 2019 OBJECTIVES: In this open trial, the efficacy of imipenem/cilastatin was investigated in 88 peritonitis episodes in 50 chronic renal failure patients on continues ambulatory peritoneal dialysis (CAPD) in one year.
Arif KAPUAGASI +5 more
doaj